Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies
NCT03913741Phase 2Completed
- Sponsor
- Genmab
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tisotumab vedotin in solid tumor, Cervical Cancer (CC), sponsored by Genmab. Started Feb 2019; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
solid tumorCervical Cancer (CC)
Beyond the preview
Go deeper on NCT03913741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913741.